Get the Stockscreener App
870.37
3.35%
28.19
After Hours:
867.30
-3.07
-0.35%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly Earnings: GLP-1 Market Growth Looks Solid - Morningstar
Lilly's Growth in Diabetes and Obesity, and Strong Oncology and Immunology Drugs Create a Wide Moat - Morningstar
Why Eli Lilly Shrugged Off its Weight-Loss Disappointment - Investor's Business Daily
Eli Lilly (LLY) Q4 2024 Earnings Call Transcript - The Motley Fool
Eli Lilly Q4 Earnings: Now The Magical $1 Trillion Dollar Market Cap Is In Sight (LLY) - Seeking Alpha
Eli Lilly, Novo Nordisk sold more than $40 billion in GLP-1 drugs in 2024 - Sherwood News
A Closer Look at Eli Lilly's Options Market Dynamics - Benzinga
Eli Lilly and Company (NYSE:LLY) Trading Up 4.1%Should You Buy? - MarketBeat
What Are Wall Street Analysts' Target Price For Eli Lilly Stock? - Barchart
Lilly reassures investors that weight-loss drug demand is strong, shares rise - Reuters
Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to Mounjaro and Zepbound - FiercePharma
Eli Lilly annual profit outlook tops expectations; stock gains - Investing.com
Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024 - 21 Alive News
Lilly’s profit doubles in fourth quarter, driven by Mounjaro and Zepbound sales - WISH TV Indianapolis, IN
Why Eli Lilly Stock Popped on Thursday - The Motley Fool
Eli Lilly Stock Rises After Profit, Outlook Top Expectations - Kiplinger's Personal Finance
Lilly’s profit forecast bring investors some relief amid Zepbound miss - PharmaLive
Lilly reports robust Q4, full-year earnings - Inside INdiana Business
Market movers: Ford, Peloton, Skyworks Solutions, Eli Lilly... - Proactive Investors USA
Eli Lilly’s Net Income Doubles And Its Revenue Grows 45% - Baystreet.ca
Eli Lilly revenue misses expectations despite strong growth in Mounjaro, Zepbound - Proactive Investors USA
Eli Lilly (LLY) Stock Rises on Strong Q4 Earnings and Bullish 2025 Outlook – market - HPBL
Zepbound sales keep soaring, even as weight loss drug growth slows - Quartz
Eli Lilly Full-Year Earnings Meet Expectations Amid GLP-1 Inventory Challenges – market - HPBL
Eli Lilly (LLY) Reports Blockbuster Q4 Revenue Growth Fueled by Mounjaro and Zepbound Sales - HPBL
Eli Lilly expects to beat profit forecasts on obesity drug demand - Financial Times
Eli Lilly forecasts 2025 profit growth after recent weight-loss drug worries - The Globe and Mail
Weight-loss drugs swell revenues at Eli Lilly - ShareCast
Eli Lilly Posts Mixed Q4 Results; Fiscal 2025 Guidance Reaffirmed - Yahoo Finance UK
Lilly issues 2025 profit view as it steers for revenue boost - MSN
Eli Lilly: 4th quarter consensus beaten -February 06, 2025 at 08:11 am EST - Marketscreener.com
Lilly Profit View ‘Enough to Pacify Investors’ After Sales Miss - BNN Bloomberg
Eli Lilly CEO reveals latest developments in Alzheimer's research - Fox Business
Eli Lilly Reports Q4 2024 Earnings: EPS at $4.88, Revenue Hits $13.53 Billion, Missing Analyst Estimates - GuruFocus.com
Mounjaro and Zepbound Sales Soar, Pushing Eli Lilly's (LLY) Q4 Revenue to New Highs - Yahoo Finance UK
Lilly forecasts 2025 profit above estimates on weight-loss drug strength - Business Standard
Eli Lilly stock rises on Q4 2024 beat (update) (LLY:NYSE) - Seeking Alpha
Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines - Yahoo Finance
Eli Lilly (NYSE:LLY) Reports Q4 In Line With Expectations, Full-Year Outlook Slightly Exceeds Expectations - Investing.com Canada
Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected - CNBC
LLY Earnings: Weight Loss Drug Demand Drives Eli Lilly Sales as Investors Eye Next-Gen Treatments - TipRanks
Eli Lilly Reports Q4 Worldwide Mounjaro Revenue Increased 60% To $3.53 Billion -February 06, 2025 at 07:15 am EST - Marketscreener.com
Eli Lilly’s Q4 2024 Revenue Surges by 45% to $13.53 Billion - The Tokenist
Eli Lilly Q4 Non-GAAP Earnings, Revenue Increase; 2025 Outlook Issued -February 06, 2025 at 07:10 am EST - Marketscreener.com
Lilly says Mounjaro and Zepbound contributed to big revenue boost - MarketWatch
Eli Lilly’s Full-Year Profit Views in Line After Recent Misses - Bloomberg
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short - CNBC
Lilly: Q4 Earnings Snapshot -February 06, 2025 at 06:57 am EST - Marketscreener.com
Eli Lilly forecasts 2025 profit largely above estimates on launch of weight-loss drug in new markets - Marketscreener.com
Bernstein reiterates Eli Lilly stock Outperform with $1,100 target - Investing.com
Eli Lilly & Co. (LLY) Tops Q4 EPS by 2c; offers outlook - StreetInsider.com
Lilly reports full Q4 2024 financial results and provides 2025 guidance - Investors | Eli Lilly and Company
Eli Lilly & Co. (LLY) call put ratio 1.6 calls to 1 put into quarter results - StreetInsider.com
Eli Lilly Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga
Eli Lilly's oral SERD becomes 1st to navigate Korea's reformed drug approval system - KBR
Eli Lilly Bulls Take Charge Ahead Of Q4 — Can It Reach $1000? - Benzinga
Erste Group raises Eli Lilly stock rating to Buy, sees strong sales - Investing.com
Truist maintains Eli Lilly stock Buy rating, $1038 target - Investing.com
1.68%
0.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):